Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election without traverse of the invention of Group I (claims 17-24, 26 and 27), and the particular marker that is RCN2 in the reply filed on 08/11/2026 is acknowledged.
Claims 25 and 28 -34 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims19 and 20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as requiring nonelected species (i.e.: the election names only RCN2, and claims 19 and 20 specially require additional particular markers), there being no allowable generic or linking claim.
Election was made without traverse in the reply filed on 08/11/2026.
Claim Objections
Claims 17 and 26 are objected to because of the following informalities:
Claim 17 is objected to because at the first instance of the recitation of the gene symbol ‘RCN2’ (as consonant with the election), the gene symbol should be accompanied by the full gene name consonant with the teachings of the specification (i.e.: reticulocalbin-2 as provided in Table A).
Claim 26 is objected to because the line 7 of the claim includes two semicolons in the phrase “in the subject;; and”, where a single semicolon is appropriate.
Appropriate corrections are required.
Objection to the Drawings
Color photographs and color drawings are not accepted in utility applications unless a petition filed under 37 CFR 1.84(a)(2) is granted. Any such petition must be accompanied by the appropriate fee set forth in 37 CFR 1.17(h), one set of color drawings or color photographs, as appropriate, if submitted via the USPTO patent electronic filing system or three sets of color drawings or color photographs, as appropriate, if not submitted via the via USPTO patent electronic filing system, and, unless already present, an amendment to include the following language as the first paragraph of the brief description of the drawings section of the specification:
The patent or application file contains at least one drawing executed in color. The brackets at the bottom of each panel of Figure 6 are red. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
Color photographs will be accepted if the conditions for accepting color drawings and black and white photographs have been satisfied. See 37 CFR 1.84(b)(2).
Claim Rejections - 35 USC § 112 - Indefiniteness
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 17, 18, 21-24, 26 and 27 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 17, 18 and 21-24 are unclear over recitation of the limitation “treating the subject identified in step (i) as having muscle atrophy”, as recited in part (ii) of claim 17, from which claims 18 and 21-24 depend. There is no antecedent basis for any “subject identified in step (i) as having muscle atrophy”; there is no identifying step recited as a part of, or required by, step (i). The practical aspects of step (i) are the determining of an expression level of RCN2 (as consonant with the election) in a sample from the subject. Determining a level is not a step of identifying. While step (i) recites a “wherein” clause, the recited clause is only a statement of some asserted property of a determined and compared expression level; it is not a requirement that such a level is in fact present and detected, and is not a step of, requirement for, identifying a subject. Furthermore, where the claims are directed to “treating muscle atrophy in a subject” (as recited in the preamble of claim 17), and step (ii) is unclear over the requirement for treating a subject (as detailed above), it is unclear how the intended purpose of the claimed methods is in fact accomplished by performing the recited process steps.
Claims 17, 18 and 21-24 are unclear over recitation of the limitation “determining the expression level of …RCN2 (SEQ ID NO:3) … in a blood sample obtained from the subject” (as consonant with the election), as recited in part (i) of claim 17, from which claims 18 and 21-24 depend. Where SEQ ID NO:3 is provided in parentheses, it is unclear if the claim is intended to require that the determining of an expression level is specifically directed to SEQ ID NO: 3 (i.e.: a human mRNA transcript of the RCN2 gene), or if SEQ ID NO: 3 is only an example of what can be detected in the determining of an expression level.
Claim 22 is rejected because the claim contains the trademark/trade name ‘nCounter’. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe reagents and systems used to determine a gene expression level and, accordingly, the identification/description is indefinite.
Claims 26 and 27 are unclear over recitation of the limitation “taking into account the presence of muscle atrophy for selecting, adapting or changing treatment in the subject”, as recited in claim 26 from which claim 27 depends. Initially it is noted that there is no antecedent basis for any “presence of muscle atrophy”. Similar to the rejection of claim 17 above, claim 26 recites a step of “assessing the presence of muscle atrophy in the subject by determining the expression level of …RCN2 … in a blood sample obtained from the subject” (as consonant with the election), and recites a “wherein” clause asserting some relationship between “a reduction in expression level of” the marker “as compared to a reference value” being “indicative of muscle atrophy in the subject”. The recited “wherein” clause is only a statement of some asserted property of a determined and compared expression level; it is not a requirement that such a level is in fact present and detected, and is not a step of, requirement for, “the presence of muscle atrophy” in a subject. Furthermore, it is noted that there is no indication of what steps or procedures are required for “taking into account” any pathology; it is unclear how any “electing, adapting or changing” of a treatment is different when any pathology is taken “into account” versus not taken “into account”. It is unclear how “taking into account” any pathology modifies, changes, or limits any “electing, adapting or changing” of a treatment.
Claim 27 is unclear over the various elements that are provided in parentheses, because it is unclear if the claim is intended to require the elements, or if each parenthetical element is only an example of what can be used in the treatment of atrophy. For example, where the claim recites “drugs (pharmacological agents such as glucocorticoids, anti-inflammatory drugs)”, it is unclear if the drugs of the claims are limited to “glucocorticoids, anti-inflammatory drugs”, or if other types of drugs are intended to be encompassed by the claim.
Claim Rejection - Improper Markush Grouping
Claims 17, 18, 21-24, 26 and 27 are rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use.
A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP § 2117.
The Markush grouping of the claims, which recites in the alternative a list of independent and distinct genes is improper because the alternatives (i.e.: the different biomarkers gene sequence) defined by the Markush grouping do not share both a single structural similarity and a common use for the following reasons:
In the instant case each different element is considered to be a method comprising analysis of a different gene sequence to determine the presence of muscular atrophy. In the instant case Applicants have elected the particular gene that is RCN2.
The recited alternative elements do not share a single structural similarity, as each method relies on detection of a different polynucleotide sequence (i.e.: a particular gene sequence). Each polynucleotide (i.e.: each different gene) has a different chemical structure in that it consists of a different nucleotide sequence. Each polynucleotide has a different biological activity in that it has a different specificity of hybridization and encodes a different protein each with different biological activity and a different role in the physiology of a cell. Thus, the different elements (e.g.: each different recited gene) do not share a single structural similarity or biological activity. The only structural similarity present is that all of the gene expression products are composed of nucleic acids. The fact that the genes are composed of nucleic acids does not per se support a conclusion that they have a common single structural similarity because the structure of comprising a nucleic acid alone is not essential to the asserted common activity of being related to the presence of muscular atrophy, as asserted by the instant application. Accordingly, while the different elements are asserted to have the property of having an expression level that may be associated with the presence of muscular atrophy, they do not share a single structural similarity essential to this activity. Here it is clear that any asserted common use does not flow from any broadly ascribed common structure (see MPEP 2117). The asserted common use of being a biomarker for muscular atrophy is particular to each different biomarker (i.e.: each particular gene a) based on the specific content of the biomarker and not based on some particular common structural feature shared among the different biomarkers.
Note that when the Markush grouping is for alternatives of chemical compounds, the alternatives are regarded as being of a similar nature where the following criteria are fulfilled:
(A) all alternatives have a common property or activity; AND
(B)(1) a common structure is present, that is, a significant structural element is shared by all of the alternatives; OR
(B)(2) in cases where the common structure cannot be the unifying criteria, all alternatives belong to a recognized class of chemical compounds in the art to which the invention pertains.
The phrase “significant structural element is shared by all of the alternatives” refers to cases where the compounds share a common chemical structure which occupies a large portion of their structures, or in case the compounds have in common only a small portion of their structures, the commonly shared structure constitutes a structurally distinctive portion in view of existing prior art, and the common structure is essential to the common property or activity.
The phrase “recognized class of chemical compounds” means that there is an expectation from the knowledge in the art that members of the class will behave in the same way in the context of the claimed invention, i.e. each member could be substituted one for the other, with the expectation that the same intended result would be achieved.
In the present situation, there is no evidence of record to establish that it is clear from their very nature that the different particular genes recited in the claims are associated with muscular atrophy. Additionally, the different biomarkers themselves behave differently, with each having different compared levels between a control and different pathologies associated with muscular atrophy (e.g.: see Figure 3 of the drawings).
Following this analysis, the claims are rejected as containing an improper Markush grouping.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 17, 18, 21-24, 26 and 27 are rejected under 35 U.S.C. 101 because the claimed invention is directed to abstract ideas and natural phenomena without significantly more.
The claim(s) recite(s) a correlation between a compared level of expression and the presence of muscle atrophy. The claims recite “a reduction in expression level of said at least one biomarker as compared to a reference value is indicative of muscle atrophy in the subject”. Where the claims are directed to determination of a presence of a treatable pathology based on a compared measure of expression levels, the claims include an abstract an abstract idea which is a mental process; the correlation of data and information to make a judgment or reach a conclusion which can be performed in the human mind (MPEP 2016.04(a)(2)(III). Such abstract ideas (i.e.: mental processes) are further embodied in the recitation of the limitation “a reduction in expression level of said at least one biomarker as compared to a reference value”, which is a comparison of data that can be performed in the human mind. Additionally, where the claims are directed to the asserted association between gene expression alterations and the presence of muscle atrophy pathology, and such genes and their relative levels of expression are a natural part of the atrophy pathology, the claims are directed to a natural phenomenon (MPEP 2106.04(b)).
This judicial exception is not integrated into a practical application because there are no clearly required practical steps performed as a result of any compared biomarker expression level. Claim 17, from which claims 18 and 21-24 depend, recites a step of “treating the subject identified in step (i) as having muscle atrophy with drugs, nutritional agents, exercise, or a combination thereof”. But as noted earlier in this Office Action, where step (i) does not recite or require and active process step of identifying a subject as having atrophy, it is not appropriate to consider step (ii) of claim 17 as requiring a practical application into which the judicial exception is integrated. Furthermore, the claims only provide broadly recited modalities of treatment, which are not actually recited as being performed to treat atrophy. For example, claim 17 includes any nutritional agent, thus providing the highest level of generality in such a treatment (see MPEP 2106.04(d)(2)(a). And the method of claim 26, from which claim 27 depends, is directed to selecting, adapting or changing a treatment, but not to any actual treatment steps. See MPEP 2106.04(d)(2):
For example, a step of "prescribing a topical steroid to a patient with eczema" is not a positive limitation because it does not require that the steroid actually be used by or on the patient, and a recitation that a claimed product is a "pharmaceutical composition" or that a "feed dispenser is operable to dispense a mineral supplement" are not affirmative limitations because they are merely indicating how the claimed invention might be used.
The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the claims recite only general steps related to the processing of samples to measure a biomarker (e.g.: mRNA level), but such methods were well understood, routine and conventional in the related art. Signorelli et al (2021) teaches transcriptomic profiling of blood samples related to muscular dystrophy, a pathology that causes muscular atrophy, and the treatment of muscular dystrophy using RNA-sequencing, which provides a measure of expression levels of every expressed RNA. .
Claim Rejections - 35 USC § 112 – Scope of Enablement
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 17, 18, 21-24, 26 and 27 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for (as consonant with the Election):
Methods of identifying muscle atrophy in a human subject, wherein a reduction in expression level of RCN2 mRNA in a blood sample from the subject as compared to the level of RCN2 mRNA in a blood sample obtained from a healthy control induvial is indicative of muscle atrophy
does not reasonably provide enablement for the claims as broadly written which encompass the detection of any RCN2 analyte (i.e.: mRNA or protein) in any subject organism and comparison to any reference value for indicating muscle atrophy. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.
Scope of the Claims/Nature of the Invention
The claims are directed to methods of the detection of RCN2 (as consonant with the election) expression levels of any analyte (e.g.: mRNA or protein) in a blood sample from any subject organism for indicating the presence of muscle atrophy with a reduction in the level of RCN2 as compared to ant reference value.
The claimed methods thus require knowledge of a reliable relationship to a variety of measured expression values in blood samples from different subject organisms and a the presence of muscle atrophy.
Teachings in the Specification and Examples
The specification (p.16 of PG Pub 2025/0236914) teaches an example of the analysis of gene expression levels determined by RNA-seq, qPCr and dPCR and in blood samples from human subjects; the specification teaches a comparison of gene expression in subject sample to samples from healthy controls (para 0189; para 203). The specification teaches (relevant to the Election), that RCN2 RNA is downregulated in atrophy subjects as compared to healthy control subjects (e.g.: Table 3).
The specification does not teach the analysis of any non-human samples.
The specification does not teach any analysis of non-mRNA analytes.
The specification does not teach any reference values of RCN2 gene expression other than the amount determined in blood samples of healthy control subjects.
State of the Art and the Unpredictability of the Art
While methods of measuring gene expression are known in the art, methods of correlating the level of gene expression with a phenotype (i.e.: the presence or absence of muscle atrophy) are highly unpredictable.
Because the specification asserts that the methods are applicable to any subject organism (e.g.: specification at para 0057), but teaches only the analysis of human samples, it is relevant to point out that it is highly unpredictable as to whether the results obtained in human subjects could be extrapolated to non-human subjects. The instant specification (e.g.: para 0008) teaches the accepted unpredictability in extrapolating non-human gene expression results to analysis of humans. And Hoshikawa et al (2003) teaches unpredictability with regard to applying gene expression results among different organisms. The reference teaches the analysis of gene expression in lung tissue in response to hypoxic conditions which lead to pulmonary hypertension (Fig. 1). The reference teaches that the gene expression profile in mouse is different from that observed in rat (Tables 1-4; p.209 -Abstract). Thus, it is unpredictable as to whether or any gene expression that is atrophy-related in humans is in fact applicable to identifying atrophy in any other non-human organism.
The specification teaches only a diagnostically relevant comparison of atrophy subjects with healthy control subjects. Because the claims broadly and generically encompass a comparison of gene expression with any “reference value”, which is broadly defined in the specification (e.g.: para 0061), it is relevant to point out that the prior art of Cheung et al (2003) teaches that there is natural variation in gene expression; so it is unpredictable if any comparison to any reference, as generically encompassed by the claims are indicative of atrophy.
Because the claims encompass the analysis of any gene expression biomarker analytes (e.g.: protein or mRNA), whereas the specification provides only the example analysis of RCN2 mRNA (as consonant with the Election), it is relevant to point out that Chen (2002) teaches that it is common for protein expression to be discordant with mRNA expression levels even in matched samples (e.g.: Figure 3). Thus, it is unpredictable as to how to extrapolate the mRNA-based teachings of the instant specification to the analysis of any other different analyte.
Quantity of Experimentation
The quantity of experimentation necessary to make and use the invention in the full scope as claimed is great, on the order of many man-years, and then with little if any reasonable expectation of successfully enabling the full scope of the claims. The experimentation would require case:control analysis of any levels of RCN2 mRNA or protein in any samples from any subjects as compared to any reference to determine presence of atrophy. Even if such extensive experimentation were to be performed, there is no indication that any associations, beyond those particular associations disclosed in the specification, would be found.
Conclusion
Although the level of skill in the art is high, given the lack of disclosure in the specification and in the prior art and the unpredictability of the art, it would require undue experimentation for one of skill in the art to make and use the invention as broadly claimed.
Conclusion
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to STEPHEN THOMAS KAPUSHOC whose telephone number is (571)272-3312. The examiner can normally be reached M-F, 8am-5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Gussow can be reached at 571-272-6047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Stephen Kapushoc
Primary Examiner
Art Unit 1683
/STEPHEN T KAPUSHOC/Primary Examiner, Art Unit 1683